BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19807094)

  • 41. Synthesis and opioid activity of 2-substituted dynorphin A-(1-13) amide analogues.
    Story SC; Murray TF; Delander GE; Aldrich JV
    Int J Pept Protein Res; 1992 Aug; 40(2):89-96. PubMed ID: 1359999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors.
    Aldrich JV; Zheng QI; Murray TF
    Chirality; 2001; 13(3):125-9. PubMed ID: 11270320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration.
    Perlikowska R; Piekielna J; Gentilucci L; De Marco R; Cerlesi MC; Calo G; Artali R; Tömböly C; Kluczyk A; Janecka A
    Eur J Med Chem; 2016 Feb; 109():276-86. PubMed ID: 26785295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N,N-diallyl-tyrosyl substitution confers antagonist properties on the kappa-selective opioid peptide [D-Pro10]dynorphin A(1-11).
    Gairin JE; Mazarguil H; Alvinerie P; Botanch C; Cros J; Meunier JC
    Br J Pharmacol; 1988 Dec; 95(4):1023-30. PubMed ID: 2905908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and biological activity of dynorphin-(1-13) and analogs substituted in positions 8 and 10.
    Lemaire S; Lafrance L; Dumont M
    Int J Pept Protein Res; 1986 Mar; 27(3):300-5. PubMed ID: 2872177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
    Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
    J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.
    Aldrich JV; Senadheera SN; Ross NC; Reilley KA; Ganno ML; Eans SE; Murray TF; McLaughlin JP
    Br J Pharmacol; 2014 Jul; 171(13):3212-22. PubMed ID: 24588614
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.
    Aldrich JV; Kulkarni SS; Senadheera SN; Ross NC; Reilley KJ; Eans SO; Ganno ML; Murray TF; McLaughlin JP
    ChemMedChem; 2011 Sep; 6(9):1739-45. PubMed ID: 21761566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynorphin peptides differentially regulate the human kappa opioid receptor.
    Chen Y; Chen C; Liu-Chen LY
    Life Sci; 2007 Mar; 80(15):1439-48. PubMed ID: 17316701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
    Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
    J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2.
    Monory K; Bourin MC; Spetea M; Tömböly C; Tóth G; Matthes HW; Kieffer BL; Hanoune J; Borsodi A
    Eur J Neurosci; 2000 Feb; 12(2):577-84. PubMed ID: 10712637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and biological activity of [MeTyr1,MeArg7,D-Leu8]-dynorphin A(1-9)-NHEt and [D-Cys2-Cys5,MeArg7,D-Leu8]-dynorphin A(1-9)-NH2.
    Yoshino H; Arakawa Y; Nakazawa T; Kaneko T; Matsunaga M; Araki S; Ikeda M; Tsuchiya Y; Yamatsu K; Tachibana S
    Chem Pharm Bull (Tokyo); 1990 Aug; 38(8):2274-6. PubMed ID: 1980641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
    Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
    Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
    J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues.
    Yoshino H; Nakazawa T; Arakawa Y; Kaneko T; Tsuchiya Y; Matsunaga M; Araki S; Ikeda M; Yamatsu K; Tachibana S
    J Med Chem; 1990 Jan; 33(1):206-12. PubMed ID: 1967312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.
    Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y
    Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
    Simpson DS; Katavic PL; Lozama A; Harding WW; Parrish D; Deschamps JR; Dersch CM; Partilla JS; Rothman RB; Navarro H; Prisinzano TE
    J Med Chem; 2007 Jul; 50(15):3596-603. PubMed ID: 17580847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
    Agnes RS; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
    J Med Chem; 2006 May; 49(10):2868-75. PubMed ID: 16686530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
    Cami-Kobeci G; Neal AP; Bradbury FA; Purington LC; Aceto MD; Harris LS; Lewis JW; Traynor JR; Husbands SM
    J Med Chem; 2009 Mar; 52(6):1546-52. PubMed ID: 19253970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.